Clinical Trial Update: Role of a CCK Receptor Antagonist Proglumide in Management of Chronic Pancreatitis [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on proglumide, a CCK receptor antagonist, for safety and pain management in chronic pancreatitis (Phase 1/Phase 2).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatitis

Drugs mentioned

• Proglumide (proglumide)

Snippet

Sponsor: Georgetown University | Conditions: Safety Issues, Pain | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING